Trisalus pressure-enabled drug delivery increased effect of anti-CEA CAR-T in pancreatic cancer patients with liver metastases

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A phase Ib clinical trial suggests that administering a concentrated dose of anti-CEA CAR-T cells precisely at the site of a solid tumor by means of TriSalus Life Sciences’ unique Pressure-enabled Drug Delivery is safe, with encouraging clinical responses.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login